Dynamics of epileptiform activity, efficacy and tolerability of valproic acid in adults and adolescents with newly-diagnosed epilepsy

Karlov V.A.; Kozhokaru A.B.; Vlasov P.N.; Pushkar T.N.; Orlova A.S.

doi:https://doi.org/10.17116/jnevro202012007135

Karlov V.A.

Evdokimov Moscow State University of Medicine and Dentistry

Kozhokaru A.B.

State Research Center — Burnasyan Federal Medical Biophysical Center

Vlasov P.N.

Evdokimov Moscow State University of Medicine and Dentistry

Pushkar T.N.

Evdokimov Moscow State University of Medicine and Dentistry

Orlova A.S.

Sechenov First Moscow State Medical Univesity

Dynamics of epileptiform activity, efficacy and tolerability of valproic acid in adults and adolescents with newly-diagnosed epilepsy

Authors:

Karlov V.A., Kozhokaru A.B., Vlasov P.N., Pushkar T.N., Orlova A.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(7): 35‑43

DOI: 10.17116/jnevro202012007135

Read: 4484 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Karlov VA, Kozhokaru AB, Vlasov PN, Pushkar TN, Orlova AS. Dynamics of epileptiform activity, efficacy and tolerability of valproic acid in adults and adolescents with newly-diagnosed epilepsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(7):35‑43. (In Russ.)
https://doi.org/10.17116/jnevro202012007135

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To evaluate the changes of epileptiform activity index (EAI) as a measure of the efficacy and tolerability of treatment with valproic acid (VA) in patients with newly-diagnosed generalized and focal epilepsy.

MATERIAL AND METHODS

The study included 93 patients (55 men and 38 women): 27 with focal epilepsy (FE) and 66 with idiopathic generalized epilepsy (IGE). Patients with idiopathic and age-dependent FE were not included in the study. At each visit, video-EEG monitoring with the analysis of focal, diffuse and generalized epileptiform activity during wakefulness before sleep, during sleep, after sleep and during partial awakenings with quantitative EAI assessment at baseline, after 1, 3, 6 and 12 months of therapy was performed. Therapeutic drug monitoring was performed during dose titration 1 month after the start of treatment or in case of treatment change. Treatment efficacy was assessed based on the absence of seizures, decrease of seizure episodes by more than 50% (responders) and <50% (insufficient efficacy). Adverse effects (AE) were assessed using the Assessing SIDe effects in AED treatment scale (SIDAED).

RESULTS

Maximal EAI was observed at baseline both in FE and IGE groups. In patients with IGE, the total EAI (52.8±7.8) was significantly higher compared to FE group (27.1±5.5 (p=0,027)). During wakefulness before sleep and during sleep EAI was significantly lower in the IGE group compared to FE patients (3.4±0. vs. 10.5±5.5 (p=0.003) and 4.3±0.8 vs. 8.9±3.7 (p=0.046), respectively). VA demonstrated the high efficacy and good tolerability in IGE and FE patients: after 12 months of treatment remission was achieved in 69 (74.2%) patients, the decrease of seizure frequency by more than 50% was observed in 22 (23,7%) patients, insufficient efficacy only in 2 (2.1%). AEs were registered only sporadically.

CONCLUSIONS

VA remains one of the drugs of choice in IGE and FE. EAI may become an additional objective test in cases of difficult differential diagnosis in IGE and FE, using total EAI, EAI before sleep, during sleep, during partial awakenings in the first months of treatment (1—3 months). EAI objectively reflects the dynamics of VA treatment efficacy.

Keywords:

idiopathic generalized epilepsy

focal epilepsy

epileptiform activity index

valproic acid

Authors:

Karlov V.A.

Evdokimov Moscow State University of Medicine and Dentistry

Kozhokaru A.B.

State Research Center — Burnasyan Federal Medical Biophysical Center

Vlasov P.N.

Evdokimov Moscow State University of Medicine and Dentistry

Pushkar T.N.

Evdokimov Moscow State University of Medicine and Dentistry

Orlova A.S.

Sechenov First Moscow State Medical Univesity

Received:

06.02.2020

Accepted:

07.02.2020

Close metadata

References:

Karlov VA. Jepilepsija u detej i vzroslyh, zhenshhin i muzhchin. Rukovodstvo dlja vrachej. M.: Binom; 2019. (In Russ.).
Karlov VA. Depakine: 25 years in Russia. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2017;117(11):129-134. (In Russ.). https://doi.org/10.17116/jnevro2017117111129-134
Muhin KJu, Gluhova LJu, Bobylova MJu. Jepilepticheskie sindromy. Diagnostika i terapija. Chetvertoe izdanie. M. 2018. (In Russ.).
Vlasov PN. Algorithms of using valproic acid drugs in women. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2015;115(4):36-40. (In Russ.). https://doi.org/10.17116/jnevro20151154136-40
Badalyan OL, Burd SG, Savenkov AA, Avakyan GG, Yutskova EV, Avakyan GN. Jepilepsija i Paroksizmal’nye Sostojanija. 2014;6(2):39-44. (In Russ.).
Khachidze I, Gugushvili M, Makashvili M, Maloletnev V. The investigation of EEG specificity in epileptic children during Depakine therapy. Int J Neurosci. 2016;126(10):912-921. https://doi.org/10.3109/00207454.2015.1083991
Appleton RE, Freeman A, Cross JH. Diagnosis and management of the epilepsies in children: a summary of the partial update of the 2012 NICE epilepsy guideline. Arch Dis Child. 2012;97(12):1073-1076. https://doi.org/10.1136/archdischild-2012-302822
Beghi E, Sander JW. The ILAE classification of seizures and epilepsies: implications for the clinic. Expert Rev Neurother. 2018;18(3):179-183. https://doi.org/10.1080/14737175.2018.1427066
Glauser TA, Loddenkemper T. Management of childhood epilepsy. Continuum (Minneap Minn). 2013;19(3 Epilepsy):656-681. https://doi.org/10.1212/01.CON.0000431381.29308.85
Zhu MM, Li HL, Shi LH, Chen XP, Luo J, Zhang ZL. The pharmacogenomics of valproic acid. J Hum Genet. 2017;62(12):1009-1014. https://doi.org/10.1038/jhg.2017.91
Karlov VA. Worldwide day of patients with epilepsy. Jepilepsija i Paroksizmal’nye Sostojanija. 2015;7(1):56. (In Russ.).
Vlasov PN, Orehova NV, Antonjuk MV, Filatova NV, Shnajder NA, Dmitrenko DV, Zobova SN, Poverennova IE, Jakunina AV, Kalinin VA, Zyrjanov SK, Tishhenkova IF. The efficacy and safety of valproic acid medications with controlled active ingredient release in adults in real clinical practice from the position of pharmacokinetic and pharmacogenetic approaches. Nevrologiya, Nejropsihiatriya, Psihosomatika. 2017;1:11-20. (In Russ.). https://doi.org/10.14412/2074-2711-2017-1S-11-20
Tomson T, Battino D, Perucca E. Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug. Lancet Neurol. 2016;15(2):210-218. https://doi.org/10.1016/S1474-4422(15)00314-2
Zenkov LR. Klinicheskaja jelektrojencefalografija (s jelementami jepileptologii). Rukovodstvo dlja vrachej. 3-e izd. M.: MIA; 2011. (In Russ.).
Clemens B, Menes A, Piros P, Bessenyei M, Altmann A, Jerney J, Kollár K, Rosdy B, Rózsavölgyi M, Steinecker K, Hollódy K. Quantitative EEG effects of carbamazepine, oxcarbazepine, valproate, lamotrigine, and possible clinical relevance of the findings. Epilepsy Res. 2006;70:190-199. https://doi.org/10.1016/j.eplepsyres.2006.05.003
Salinsky MC, Oken BS, Storzbach D, Dodrill CB. Assessment of CNS effects of antiepileptic drugs by using quantitative EEG measures. Epilepsia. 2003;44:1042-1050. https://doi.org/10.1046/j.1528-1157.2003.60602.x
Schmidt D, Löscher W. Uncontrolled epilepsy following discontinuation of antiepileptic drug in seizurefree patients: a review of current clinical experience. Acta Neurologica Scandinavica. 2005;111:291-300. https://doi.org/10.1111/j.1600-0404.2005.00408.x
Pasternak EYu, Alyautdin RN, Asetskaya IL, Romanov BK. The problems of the interchangeability of antiepileptic drugs: efficacy and safety of valproates. Nevrologicheskij Zhurnal. 2015;5:34-39. (In Russ.). https://doi.org/10.18821/1560-9545-2015-20-5-34-39
Fisher RS. An Overview of the 2017 ILAE Operational Classification of Seizure Types. Epilepsy Behav. 2017;70(Pt A):271-273. https://doi.org/10.1016/j.yebeh.2017.03.022
Uijl SG, Uiterwaal CS, Aldenkamp AP, Carpay JA, Doelman JC, Keizer K, Vecht CJ, de Krom MC, van Donselaar CA. A cross-sectional study of subjective complaints in patients with epilepsy who seem to be well-controlled with anti-epileptic drugs. Seizure. 2006;15(4):242-248. https://doi.org/10.1016/j.seizure.2006.02.009
Nevitt SJ, Sudell M, Weston J, Tudur Smith C, Marson AG. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev. 2017;12:CD011412. https://doi.org/10.1002/14651858.cd011412.pub2
Karlov VA, Vlasov PN, Habibova AO. Depakin 300 and Depakin-hrono for epilepsy treatment. Zhurnal Nevrologii i Psihiatrii im. C.C. Korsakova. 1999;10:20-25. (In Russ.).
Belousova ED. Russian observational study of the efficacy and tolerability of depakine chrono as first-line monotherapy for focal epilepsy. Nevrologiya, Nejropsihiatriya, Psihosomatika. 2010;3:47-52. (In Russ.).
Jedrzejczak J, Kuncikova M, Magureanu S. VIPe Study Group. An observational study of first — line valproate monotherapy in focal epilepsy. Eur J Neurol. 2008;15:66-72. https://doi.org/10.1111/j.1468-1331.2007.02003.x
Huang DH, Zheng JO, Chen J, Yu L. Treatment gaps of epilepsy and retention rates of sodium valproate in rural Guangxi, China. Genet Mol Res. 2014;13(3):6202-6312. https://doi.org/10.4238/2014.august.15.3
Sala-Padró J, Toledo M, Santamarina E, González-Cuevas M, Raspall-Chaure M, Sueiras-Gil M, Quintana M, Salas-Puig X. Levetiracetam and Valproate Retention Rate in Juvenile Myoclonic Epilepsy. Clin Neuropharmacol. 2016;39(6):299-301. https://doi.org/10.1097/wnf.0000000000000177
Deleu D, Al-Hail H, Mesraoua B, Mahmoud HA; Gulf Vipe Study Group. Short-term efficacy and safety of valproate sustained-release formulation in newly diagnosed partial epilepsy VIPe-study. A multicenter observational open-label study. Saudi Med J. 2007;28(9):1402-1407. https://doi.org/10.1111/j.1468-1331.2008.02162.x
Kutschenko A, Nitsche MA, Sommer M, Gileles E, Paulus W. Seizure aggravation by valproate in primary generalized epilepsy. Nervenarzt. 2011;82(2):226, 228-229. https://doi.org/10.1007/s00115-010-3080-y
May TW. Assessment of adverse effects of antiepileptic drugs: The patient’s view. Epileptology. 2013;1:46-54. https://doi.org/10.1016/j.epilep.2013.01.003
Urigüen JA, García-Zapirain B, Artieda J, Iriarte J, Valencia M. Comparison of background EEG activity of different groups of patients with idiopathic epilepsy using Shannon spectral entropy and cluster-based permutation statistical testing. PLoS One. 2017;12(9):e0184044. https://doi.org/10.1371/journal.pone.0184044